RecruitingNCT06091319

Florbetaben for Imaging of Vascular Amyloid

Florbetaben for Imaging of Vascular Amyloid: Evaluation of Amyloid Inflammasome Imaging in Carotid and Coronary Arteries in Patients With Unstable Atherosclerosis- A Pilot Study

Sponsor

Ottawa Heart Institute Research Corporation

Enrollment

30 participants

Start Date

Oct 9, 2023

Study Type

OBSERVATIONAL

Conditions

Stroke Acute Coronary Syndrome Transient Ischemic Attack Atherosclerosis of Artery

Summary

The Primary Objective is to determine if a new nuclear tracer (named 18F-Florbetaben) used with nuclear imaging (PET imaging) can detect inflamed plaque in patients with recent ACS or stroke/TIA.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

suffered a recent cardiovascular event (30-120 days post ACS (i.e. STEMI or NSTEMI) or TIA/stroke with ipsilateral large vessel atherosclerotic disease confirmed on US, CT or MRI;
stable symptoms and hemodynamics;
age \>/= 18 years;
given informed consent.

Exclusion Criteria11

a recent CV event likely to have been embolic in the opinion of the neurologist or cardiologist;
severe LV dysfunction (EF\<30%);
severe valve disease requiring intervention;
decompensated heart failure;
pregnancy (all women of child bearing potential will have a negative BHCG test;
breastfeeding;
women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception;.
unable to give informed consent;.
Florbetaben allergy;
glomerular filtration rate (GFR) \<50 ml/min/1.72m2
Exclusion for CTA portion of the protocol: Patients with dye allergy, or those with GFR \<60, will not undergo CTA but will have PET/CT.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.